Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark ...
bdtonline.com
news
2022-10-19 06:04:15

Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicinesFinancing led by M Venturesalongsideothernew investorsJJDC, Pfizer VenturesandBritish PatientCapital,andincludingfounding investorOxford ScienceEnterprisesNucleome'spioneeringplatformseeks toidentifydirect genetic linkages todisease-associated genesfor drug discoveryFunds will advanceNucleome'sautoimmune disease programmesandfuelexpansion ofitsdarkgenomeatlasOxford, UK, 19 October 2022 – Nucleome Therapeutics Limited, (‘Nucleome' or ‘the Company'), a biotechnology company decoding the dark matter of the human genome to discover first-in-class precision medicines, today announces it has closed an oversubscribed £37.
